Prinzipien der individualisierten, zielgerichteten Therapie am Beispiel des nicht-kleinzelligen Bronchialkarzinoms

Schlüsselwörter

nicht-kleinzelliges Bronchialkarzinom - zielgerichtete Therapie - monoklonale Antikörper

Keywords

non-small cell lung cancer - targeted drugs - monocolonal antibodies

Literatur

• 1 Balak M N. et al . Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.  Clin Cancer Res. 2006;  12 6494-6501
• 2 Engelman J A, Zejnullahu K, Mitsudomi T. et al . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.  Science. 2007;  316 1039-1043
• 3 Gandhi J. et al . Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.  PLoS One. 2009;  4 e4576
• 4 Heukamp L, Wolf J, Büttner R. Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung.  Der Internist. 2011, im Druck; 
• 5 Kobayashi S, Boggon T J, Dayaram T. et al . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2005;  352 786-792
• 6 Kwak E L, Sordella R, Bell D W. et al . Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.  Proc Nat Acad Sci. 2005;  102 7665-7670
• 7 Kwak E L, Bang Y J, Camidge D R. et al . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.  N Engl J Med. 2010;  363 1693-1703
• 8 Lynch T J, Bell D W, Sordella R. et al . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
• 9 Marchetti A. et al . Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.  Neoplasia. 2009;  11 1084-1092
• 10 Marteilli M P, Hernandez L, Pettirossi V. et al . EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.  Am J Pathol. 2009;  174 661-670
• 11 Mok T S, Wu Y L, Thongprasert S. et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.  N Engl J Med. 2009;  361 947-957
• 12 Nogova L, Boellaard R, Kobe C. et al . Downregulation of [18F]-2-Fluoro-2-Deoxy-D-Glucose Uptake in Positron Emission Tomography as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.  J Nucl Med. 2009;  DOI: 10.2967/jnumed.109.065367
• 13 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.  Brit Med J. 1995;  311 899-909
• 14 Paez J G, Janne P A, Lee J C. et al . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
• 15 Pao W, Miller V A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.  J Clin Oncol. 2005;  23 2556-2568
• 16 Pao W, Miller V A, Politi K A. et al . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.  PLoS Med. 2005;  2 e73
• 17 Regales L, Gong Y, Shen R. et al . Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.  J Clin Invest. 2009;  119 3000-3010
• 18 Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.  Clin Cancer Res. 2006;  12 7222-7231
• 19 Rosell R, Moran T, Queralt C. et al . Screening for epidermal growth factor Receptor Mutations in Lung Cancer.  N Engl J Med. 2009;  361 958-967
• 20 Sandler A, Gray R, Perry M C. et al . Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer.  N Engl J Med. 2006;  355 2542-2550
• 21 Schiller J H, Harrington D, Belani C P. et al . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.  N Engl J Med. 2002;  346 92-98
• 22 Shepherd F A, Rodrigues Pereira J, Ciuleanu T. et al, National Cancer Institute of Canada Clinical Trials Group . Erlotinib in previously treated non-small-cell lung cancer.  N Engl J Med. 2005;  14; 353 123-132
• 23 Soda M, Choi Y L, Enomoto M. et al . Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer.  Nature. 2007;  448 561
• 24 Stroobants S, Goeminne J, Seegers M. et al . 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).  Eur J Cancer. 2003;  39 2012-2020
• 25 Weiss J, Sos M L, Seidel D. et al . Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer.  Sci Transl Med. 2010;  62 62ra93
• 26 Yamamoto H. et al . PIK3CA mutations and copy number gains in human lung cancers.  Cancer Res. 2008;  68 6913-6921
• 27 Yousem S A, Nikiforova M, Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.  Am J Surg Pathol. 2008;  32 1317-1321
• 28 Zander T, Scheffler M, Nogova L. et al . Early prediction of non-progression in advanced non-small cell lung cancer treated with erlotinib using [18F]fluorothymidine and [18F]fluorodeoxyglucose positron emission tomography.  J Clin Oncol. im Druck
• 29 Miller V A. et al . Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1).   Annual Meeting Europ Soc Med Oncol (ESMO), Mailand, Oktober 2010: Abstract ID: LBA1